Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 182, Issue 6, Pages 1694-1701Publisher
OXFORD UNIV PRESS INC
DOI: 10.1086/317602
Keywords
-
Categories
Funding
- NIAID NIH HHS [AI-21548, AI-40645] Funding Source: Medline
Ask authors/readers for more resources
Pneumococcal surface protein A (PspA), a cross-reactive protein expressed by all pneumococci, is known to elicit an antibody in animals that can passively protect mice from infection with Streptococcus pneumoniae. A phase I trial with recombinant PspA showed the protein to be immunogenic in humans. Pre- and postimmune serum samples from this trial were examined, and human antibody to PspA could protect mice from pneumococcal infection. The serum samples of subjects immunized twice with 125 mug of PspA had >100 times as much antibody per milliliter as was required to consistently protect mice from fatal infection (1.3 mug/dose). At least 98% of PspAs fall into PspA sequence/serologic families 1 or 2. Human antibodies elicited by a family 1 PspA protected against infection with S. pneumoniae expressing either family 1 or 2 PspAs and with strains of all 3 capsular types tested: 3, 6A, and 6B. These studies suggest that PspA may have efficacy as a human vaccine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available